Academic Bibliography

 Search 200 years of publications by Ghent University researchers.
Advanced search
1 file | 4.26 MB
Add to list
  1. Search results
  2. De novo design of a biologically acti...

De novo design of a biologically active amyloid

Rodrigo Gallardo, Meine Ramakers, Frederik De Smet (UGent) , Filip Claes, Ladan Khodaparast, Laleh Khodaparast, José R Couceiro, Tobias Langenberg, Maxime Siemons, Sofie Nyström, et al.
(2016) SCIENCE. 354(6313).
Author
Organization
Abstract
Most human proteins possess amyloidogenic segments, but only about 30 are associated with amyloid-associated pathologies, and it remains unclear what determines amyloid toxicity. We designed vascin, a synthetic amyloid peptide, based on an amyloidogenic fragment of vascular endothelial growth factor receptor 2 (VEGFR2), a protein that is not associated to amyloidosis. Vascin recapitulates key biophysical and biochemical characteristics of natural amyloids, penetrates cells, and seeds the aggregation of VEGFR2 through direct interaction. We found that amyloid toxicity is observed only in cells that both express VEGFR2 and are dependent on VEGFR2 activity for survival. Thus, amyloid toxicity here appears to be both protein-specific and conditional-determined by VEGFR2 loss of function in a biological context in which target protein function is essential.
Keywords
PROTEIN AGGREGATION, ALPHA-SYNUCLEIN, NEURODEGENERATIVE DISEASES, ALZHEIMERS-DISEASE, GLOBULAR-PROTEINS, A-BETA, SEQUENCE, FIBRILS, SPECIFICITY, PEPTIDES

Downloads

  • Download
    (...).pdf
    • full text
    • |
    • UGent only
    • |
    • binary/octet-stream
    • |
    • 4.26 MB

Citation

Please use this url to cite or link to this publication:

MLA
Gallardo, Rodrigo, et al. “De Novo Design of a Biologically Active Amyloid.” SCIENCE, vol. 354, no. 6313, 2016, doi:10.1126/science.aah4949.
APA
Gallardo, R., Ramakers, M., De Smet, F., Claes, F., Khodaparast, L., Khodaparast, L., … Rousseau, F. (2016). De novo design of a biologically active amyloid. SCIENCE, 354(6313). https://doi.org/10.1126/science.aah4949
Chicago author-date
Gallardo, Rodrigo, Meine Ramakers, Frederik De Smet, Filip Claes, Ladan Khodaparast, Laleh Khodaparast, José R Couceiro, et al. 2016. “De Novo Design of a Biologically Active Amyloid.” SCIENCE 354 (6313). https://doi.org/10.1126/science.aah4949.
Chicago author-date (all authors)
Gallardo, Rodrigo, Meine Ramakers, Frederik De Smet, Filip Claes, Ladan Khodaparast, Laleh Khodaparast, José R Couceiro, Tobias Langenberg, Maxime Siemons, Sofie Nyström, Laurence J Young, Romain F Laine, Lydia Young, Enrico Radaelli, Iryna Benilova, Manoj Kumar, An Staes, Matyas Desager, Manu Beerens, Petra Vandervoort, Aernout Luttun, Kris Gevaert, Guy Bormans, Mieke Dewerchin, Johan Van Eldere, Peter Carmeliet, Greetje Vande Velde, Catherine Verfaillie, Clemens F Kaminski, Bart De Strooper, Per Hammarström, K Peter R Nilsson, Louise Serpell, Joost Schymkowitz, and Frederic Rousseau. 2016. “De Novo Design of a Biologically Active Amyloid.” SCIENCE 354 (6313). doi:10.1126/science.aah4949.
Vancouver
1.
Gallardo R, Ramakers M, De Smet F, Claes F, Khodaparast L, Khodaparast L, et al. De novo design of a biologically active amyloid. SCIENCE. 2016;354(6313).
IEEE
[1]
R. Gallardo et al., “De novo design of a biologically active amyloid,” SCIENCE, vol. 354, no. 6313, 2016.
@article{8508286,
  abstract     = {{Most human proteins possess amyloidogenic segments, but only about 30 are associated with amyloid-associated pathologies, and it remains unclear what determines amyloid toxicity. We designed vascin, a synthetic amyloid peptide, based on an amyloidogenic fragment of vascular endothelial growth factor receptor 2 (VEGFR2), a protein that is not associated to amyloidosis. Vascin recapitulates key biophysical and biochemical characteristics of natural amyloids, penetrates cells, and seeds the aggregation of VEGFR2 through direct interaction. We found that amyloid toxicity is observed only in cells that both express VEGFR2 and are dependent on VEGFR2 activity for survival. Thus, amyloid toxicity here appears to be both protein-specific and conditional-determined by VEGFR2 loss of function in a biological context in which target protein function is essential.}},
  articleno    = {{aah4949}},
  author       = {{Gallardo, Rodrigo and Ramakers, Meine and De Smet, Frederik and Claes, Filip and Khodaparast, Ladan and Khodaparast, Laleh and Couceiro, José R and Langenberg, Tobias and Siemons, Maxime and Nyström, Sofie and Young, Laurence J and Laine, Romain F and Young, Lydia and Radaelli, Enrico and Benilova, Iryna and Kumar, Manoj and Staes, An and Desager, Matyas and Beerens, Manu and Vandervoort, Petra and Luttun, Aernout and Gevaert, Kris and Bormans, Guy and Dewerchin, Mieke and Van Eldere, Johan and Carmeliet, Peter and Vande Velde, Greetje and Verfaillie, Catherine and Kaminski, Clemens F and De Strooper, Bart and Hammarström, Per and Nilsson, K Peter R and Serpell, Louise and Schymkowitz, Joost and Rousseau, Frederic}},
  issn         = {{0036-8075}},
  journal      = {{SCIENCE}},
  keywords     = {{PROTEIN AGGREGATION,ALPHA-SYNUCLEIN,NEURODEGENERATIVE DISEASES,ALZHEIMERS-DISEASE,GLOBULAR-PROTEINS,A-BETA,SEQUENCE,FIBRILS,SPECIFICITY,PEPTIDES}},
  language     = {{eng}},
  number       = {{6313}},
  pages        = {{9}},
  title        = {{De novo design of a biologically active amyloid}},
  url          = {{http://doi.org/10.1126/science.aah4949}},
  volume       = {{354}},
  year         = {{2016}},
}
Altmetric
View in Altmetric
Web of Science
Times cited: